126 related articles for article (PubMed ID: 29522753)
1. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin.
Li K; Yan H; Guo W; Tang M; Zhao X; Tong A; Peng Y; Li Q; Yuan Z
Exp Cell Res; 2018 May; 366(1):24-33. PubMed ID: 29522753
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.
McCabe N; Hanna C; Walker SM; Gonda D; Li J; Wikstrom K; Savage KI; Butterworth KT; Chen C; Harkin DP; Prise KM; Kennedy RD
Cancer Res; 2015 Jun; 75(11):2159-65. PubMed ID: 25870146
[TBL] [Abstract][Full Text] [Related]
4. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells.
Chen JH; Zhang P; Chen WD; Li DD; Wu XQ; Deng R; Jiao L; Li X; Ji J; Feng GK; Zeng YX; Jiang JW; Zhu XF
Autophagy; 2015; 11(2):239-52. PubMed ID: 25701194
[TBL] [Abstract][Full Text] [Related]
5. Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin.
Lv J; Qian Y; Ni X; Xu X; Dong X
Tumour Biol; 2017 Mar; 39(3):1010428317694307. PubMed ID: 28347251
[TBL] [Abstract][Full Text] [Related]
6. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
[TBL] [Abstract][Full Text] [Related]
7. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
[TBL] [Abstract][Full Text] [Related]
9. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
10. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
11. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
12. ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity.
Ali R; Alabdullah M; Miligy I; Normatova M; Babaei-Jadidi R; Nateri AS; Rakha EA; Madhusudan S
Cells; 2019 Oct; 8(10):. PubMed ID: 31635307
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
[TBL] [Abstract][Full Text] [Related]
15. New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors.
Folk WP; Kumari A; Iwasaki T; Cassimere EK; Pyndiah S; Martin E; Homlar K; Sakamuro D
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948122
[TBL] [Abstract][Full Text] [Related]
16. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin.
Domínguez-Gómez G; Díaz-Chávez J; Chávez-Blanco A; Gonzalez-Fierro A; Jiménez-Salazar JE; Damián-Matsumura P; Gómez-Quiroz LE; Dueñas-González A
Oncol Rep; 2015 Feb; 33(2):721-8. PubMed ID: 25504347
[TBL] [Abstract][Full Text] [Related]
18. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress.
Bassi C; Ho J; Srikumar T; Dowling RJ; Gorrini C; Miller SJ; Mak TW; Neel BG; Raught B; Stambolic V
Science; 2013 Jul; 341(6144):395-9. PubMed ID: 23888040
[TBL] [Abstract][Full Text] [Related]
19. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
